Overview

Dose-Titration Study of Sevelamer Carbonate in Chronic Kidney Disease (CKD) Patients on Hemodialysis

Status:
Completed
Trial end date:
2010-09-01
Target enrollment:
Participant gender:
Summary
The study aims to evaluate the efficacy and safety of sevelamer carbonate in reducing serum phosphorus and serum lipids (total and LDL-cholesterol) in Chronic Kidney Disease Patients on dialysis.
Phase:
Phase 3
Details
Lead Sponsor:
Genzyme, a Sanofi Company
Treatments:
Sevelamer